York-based rapid test kit company Abingdon Health has won a new €2million (£1.7m) contract win with a leading European biotech company for the continued development and regulatory approval of a companion diagnostic lateral flow point of care test.
After the successful completion of the feasibility stage of the development process, Abingdon has signed a Master Service Agreement (“MSA”) which covers the optimisation, scaleup, technical transfer and manufacturing of the completed product alongside comprehensive regulatory support.
RECOMMENDED READING:
- Abingdon Health is working to improve bird flu testing kits
- Abingdon Health launches Salistick™ testing kits in Europe
Abingdon Health says much of the project and associated revenue will occur in 2026.
The project also highlights the strength of its contract development and manufacturing offering.
Executive Chairman Dr Chris Hand said: “Our approach is to offer customers a complete diagnostic solution; from concept to commercial success and we are pleased to see this resonating well with customers as evidenced by this contract win. Our expertise in companion diagnostics product development is increasingly a major differentiator.”
“In this contract we are fully managing the companion diagnostic development process alongside our client’s therapeutic drug development process which adds significant complexity. Our expertise across both the development and regulatory aspects of companion diagnostic product development gives the customer piece of mind that the overall project will be managed effectively under one roof.”
Share